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The amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects the 
motor neurons (MTNs) of the central nervous system (CNS) causing the loss of 
enervation of these neurons with the muscles. ALS patients lose their mobility 
progressively due to the muscle enervation loss. At the end, internal muscles are 
affected by the constant loss of MTNs, and the patients die from respiratory depression 
due to the lack of MTNs enervating the smooth muscles allowing the lungs to function. 
Despite this fatal prognosis, the cure still unknown and there is no treatment allowing 
possible chronification. The only treatment that has shown a small survival elongation 
between 3 and 5 months is Riluzole, a blocker of glutamate receptor that avoids 
excitotoxic over stimulation in MTNs. Riluzole was approved in 1994 and since then, 
until 2017 with the approval of Edaravone, no more active compounds have been 
approved to deal with the disease. The fact that etiologic cause is not established yet, the 
molecular mechanisms, the animal models in which preclinical trials are developed, as 
well as the approach of clinical trials in humans, play an important role on the disease, 
which has represented a challenge to the scientific community for more than 150 years. 
Despite all the complications, the volume of new active compounds is at its highest 
point, and the new innovative therapies currently in phase II / III clinical trials provide 
new horizons for patients, relatives and researchers. In this report, we try to find the 
causes for this rugged therapeutic development behind ALS, scrutinizing all the 
possible defects and discussing possible solutions treat within the scientific community. 
At the same time, the report tries to convey an overview of the current knowledge about 
ALS, keeping the focus on biochemical processes and exclusively drug therapy of the 
disease. 
Resum 
L’esclerosi lateral amiotròfica (ELA) és una malaltia neurodegenerativa que afecta  les 
motoneurones del sistema nerviós central provocant la pèrdua d’enervació d’aquestes 
neurones amb els músculs. Els pacients que la pateixen perden la mobilitat 
progressivament fins que els músculs interns es veuen afectats per la pèrdua constant de 
motoneurones fins que moren de depressió respiratòria per la falta d’enervació als 
músculs llisos que permeten el funcionament dels pulmons. Tot i aquesta prognosi fatal 
de la malaltia, encara no hi ha cura coneguda ni cap tractament que permeti cronificar-
ne els efectes. L’únic tractament que ha demostrat un petit l’allargament entre 3 i 5 
mesos de vida es tracta de Riluzole un bloquejador de l’estimulació del receptor de 
glutamat que evita una sobrestimulació excitotòxica en les motoneurones. Riluzole va 
ser aprovat l’any 1994 i des de llavors fins a 2017 amb l’aprovació d’Edaravone, no 
s’han aprovat més principis actius per fer front a la malaltia. Les causes etiològiques 
encara no establertes, els mecanismes moleculars patològics, els models animals en els 
quals es desenvolupen els assaigs preclínics, així com el plantejament dels assaigs 
clínics en humans  juguen, cadascun, el seu paper en aquesta malaltia que representa tot 
un repte per a la comunitat científica des de fa més de 150 anys. Malgrat totes les 
complicacions, el volum de nous principis actius es troben al seu punt més alt, i les 
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noves teràpies innovadores actualment en fase II/III d’assaigs clínics proporcionen nous 
horitzons per a pacients, familiars i investigadors. En aquest treball s’intenta trobar les 
causes per aquest accidentat desenvolupament terapèutic darrere l’ELA, posant sota 
escrutini tots els possibles defectes i  discutir possibles solucions debatudes dins la 
comunitat científica. Al mateix temps, transmetre una visió general del coneixement 
actual sobre l’ELA, mantenint el focus en els processos bioquímics i la teràpia 
exclusivament  farmacològica de la malaltia. 
2. Introduction 
2.1. Natural history  
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease causing a 
progressive death of the Motor Neurons (MTNs)
1
. This type of neuron whose cells 
bodies are located in the brain or the spinal cord, enervate the muscles and glands. The 
lack of MTNs results in the atrophy and degeneration of the muscle that supply, 
inducing a progressive control lost of the muscles that end with the death of the patient 
due to a respiratory failure between 3 and 5 years after the disease onset. Nonetheless, 
the life expectancy is variable and 10% of patients will survive ten years on average, 
and 5% will live 20 years or more
1
.  
ALS prognosis is dreadful. It starts before even the first symptoms are noticed. 
Approximately 80% of the MTNs are already lost at the time of the diagnosis
2
. This is a 
consequence of the processes of denervation and reinnervation that take place between 
the MTNs affected by the disease and those that are still healthy. The process of 
denervation is the loss of connection between MTNs and the motor endplates of the 
muscle, mostly due to the death of the first ones
3
. When a motor neuron dies, fibers that 
belong to healthy motor neurons develop “sprouts” and take over the neural control of 
denervated muscle fibers. This phenomenon is called the reinnervation process (see 
figure 1). As long as the balance between denervation and reinnervation is maintained, 
muscle weakness may not become clinically apparent. 
 






Once the process of reinnervation process is insufficient to mask the degeneration of the 
MTNs, the symptoms start to be noticeable. First, patients experiment with the muscle 
weakness. It can start with experiencing awkwardness when walking or if arms are the 
first affected, difficulty with tasks requiring manual dexterity. Then these first 
symptoms could degenerate to atrophy, and muscle spasms
4
. The parts of the body 
affected by early symptoms of ALS depend on which motor neurons in the body are 
damaged first (see figure 2)
5
. If upper MTNs, found in the brain, are affected first, the 
patients could develop the inability to swallow (Dysphagia), speaking or forming words 
(Dysarthria), control the salivation (Drooling), or develop an excessive production of 
saliva (Sialorrhea). Language and, executive dysfunction troubles with social 
cognition and verbal memory are the most commonly reported cognitive symptoms in 
ALS
6
. Sensory nerves and the autonomic nervous system generally remain unaffected, 
meaning the majority of people with ALS maintain hearing, sight touch, smell, and 
taste. 
 
Figure 2. Diagram of the neural motor system
7
.  
ALS progression is not always a straight line. It is not uncommon to have periods 
lasting weeks to months where it is very little or no loss of function
1
. As the disease 
develops, patients experiment with spasticity, exaggerated reflexes (hyperreflexia) and 
an abnormal reflex commonly called Babinski's sign
6
.  In the final stages, patients are 
unable to speak or swallow, have a lot of aspiration difficulties and painful 
laryngospasms and lose the ability to initiate and control all voluntary movement, 
although the muscles responsible for eye movement are usually spared until the final 
stages of the disorder (see figure 3). In the end, as it was said, patients die from 




Figure 3. ALS patient. (A) The patient needs assistance from family members to stand. (B) Advanced 
atrophy of the tongue. (C) There is upper limb and truncal muscle atrophy with a positive Babinski sign. 




After all, since the French physician, Jean-Martin Charcot in 1874, establishing a 
complete clinical spectrum and specific examination features
9
, ALS stills a big 
unknown for the neuroscientist community. However, the 2000s more and more 
researchers start to investigate about ALS spurred by ALS patients foundations, new 
founding directed to it and the intellectual challenge. More and more information has 
been actualized about the disease at the point of revolutionizing all known until now. 
For example, it has been proposed that ALS could be a conjunction of different diseases 
that express the same process of neurodegeneration. Recent evidence regarding the 
epigenetic mechanism of ALS and the wide variability between patients has lead 
researchers to this hypothesis. Therefore new hopes for familiar and patients are 
delivered every week. 
In Catalonia ALS is speculated to be 400 people affected, being a total of 4000 people 
in all Spain
10
. On average, someone is diagnosed with or loses his life from ALS every 
90 minutes
1
. The disease has an incidence of 1–5 per 100,000 inhabitants and a 
prevalence of 6 cases per 100,000 inhabitants, and affects adults between 50 and 75 
years of age principally. It is important to clarify that ALS is not contagious and occurs 
throughout the world with no racial, ethnic, sex or socioeconomic boundaries
11
.  
2.3. Primary cause and primary mechanism 
2.3.1 Genetic basis 
The primary cause of this dreadful disease is still unknown. No environmental or 
physical cause has been linked directly. However, several genetic mutations have been 
linked to ALS development
12
. In roughly 10% of ALS cases, patients have one of these 
mutations, also found in other family members; these cases are called familial ALS 
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(fALS) cases. The other 90% of ALS cases have no familial relation, even though the 
cause could be a genetic mutation as well. These types of non-familiar related ALS 
cases are called sporadic ALS (sALS). It is estimated that almost 15% of sALS cases 
are caused by a genetic mutation
2
. The rest of sALS cases are not related to any genetic 
cause known yet. Since the mutation of superoxide dismutase 1 (SOD1) gene was 
linked to ALS pathogenesis in 1993
13
, the theory of a genetical cause behind ALS 
pathogenesis is still being discussed spurred on the new gene linkage discoveries 
happening every week. Today, high numbers of mutations of SOD and other genes have 
been linked to ALS (consult all of them at alsresearchfoundation.com
7
). The most 
predominant ones in ALS pathogenesis are the followings: 
1. Mutations in the superoxide dismutase-1 (SOD1) gene account for 20% of all 
fALS cases. The enzyme SOD1 normally functions as an antioxidant, helping to 
eliminate potentially damaging free radicals in cells throughout the body. The 
damage to this gene causes the production of a toxic SOD1 protein that damages 




2. The mutation of the TARDBP gene which codifies for the TDP-43 protein is 
responsible for 2-5% of fALS cases. TDP-43 is a nuclear protein involved in 
RNA transcription, splicing and transport. Under cell stress conditions, this 
protein moves to the cytoplasm, forming stress granules
14
. Stress granules 
contain non-translating mRNAs, translation initiation components, and many 
additional proteins affecting mRNA function. Moreover, stress granules have 
been proposed to affect mRNA translation and stability, as well as being linked 




3. Abnormally expanded GGGGCC hexanucleotide intronic repeats in C9orf72 
gene were identified as the most common genetic cause of fALS (40% of fALS 
cases)
16
. The first intron could be repeated to 100s or even 1,000s times
17
.  
Several cytotoxic mechanisms have been described for C9orf72. One of the 
most discussed is the possibility that these RNA repetitions were toxic “per se”.  
RNA hexanucleotides repeat form complex structures which result in 
transcriptional impediments and in the accumulation of abortive transcript that 




4. Mutations in the DNA codifying the RNA-binding protein fused in sarcoma 
(FUS) have been identified as another protein involved in ALS
19
. FUS mutations 
are estimated to be responsible for 5% of fALS cases. FUS is a protein that has 
the ability to bind nucleic acids. Moreover, like TDP-43, FUS is mainly nuclear 
and under stress conditions form cytoplasmatic granules.  
Even though, genetics plays a key role in the understanding ALS pathology, some 
patients present clinical heterogeneity showing different disease site and age onsets 
carrying the same mutation
20
. Also, sALS and fALS patients are clinically 
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2.3.2 Epigenetical involvement 
Several neurotoxic components had been proposed to be a subjacent cause to ALS, such 
as heavy metals (mainly aluminum, selenium, mercury and lead), sarín and cyclosarín, 
diets rich in β-methyl-amino-L-alanine, etc. Nonetheless, there exist mixed data on the 
topic, and no stable relation has been establishing between these neurotoxic agents as an 
ALS primary cause
22
. Nowadays these exposures are considered one of the several 
environmental factors that affect the curse of developing ALS, together with: age, 
genetic factors, and diet among others.  
The fact that environmental factors and genetic factors cannot explain the inherent cause 
of ALS, has brought epigenetic as a potential convergence between them that could 
explain what remains unclear. Epigenetic is the structural adaptation of chromosomal 
regions so as to register, signal, or perpetuate altered activity states, and includes a 
variety of mechanism such as, methylation, histone remodeling, RNA editing and 
noncoding RNAs such as microRNAs
21
. The involvement of epigenetic mechanisms in 




DNA methylation is a mechanism for gene regulation engaged by DNA 
methyltransferase (DNMT) catalyzed methyl group transfer to carbon-5 in cytosine 
residues
24
. The transcription of methylated DNA is disturbed due to methyl binding 
proteins that occupy the polymerase binding site or because activating transcription 
factors cannot bind to the methylated DNA. Methylation marks on DNA can be 
eliminated actively if the methyl group is removed through a series of enzymatic 
reactions. Interestingly, if the methylation occurs in the gene body or distal promoter 




Recent genome-wide analyses have found differential gene methylation in human 
ALS
24
. These genes are engaged in calcium homeostasis, neurotransmission and 
oxidative stress pathways which could explain the pathophysiological mechanisms
23
. In 
addition, DNA methylation is increased in ALS  
independently of age onset, meaning that factor beyond the patient age could play a 
significant role. Hypermethylation of the C9ofr72 promoter plays an important role in 
neuroprotection and is associated with expanded hexanucleotide repeats. This leads to 
decreased promoter activity, which results in reduced gene expression and lower protein 
levels stopping the protein and RNA aggregates to form
23
. These hexanucleotide repeats 
in the C9orf72 gene also reduce gene expression due to histone acetylation. Histone 
acetylation occurs on lysine residues, where acetyl groups neutralize the lysine’s 
positive charge, which leads to weaker interactions between histones and DNA and 
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enables gene transcription. The removal of acetylation marks reestablishes the positive 
charge on lysine residues and condenses the chromatin structure.  
However, the most important epigenetically discovery was finding deregulated mature 
microRNAs on postmortem human spinal cord tissue
25 
and leukocytes of sALS 
patient
23
. MiRNAs are evolutionarily conserved noncoding RNAs, about 22 nucleotides 
long, which can individually regulate several hundred targets via RNA-dependent 
posttranscriptional silencing mechanism
26
. A single miRNA can regulate several 
hundred mRNA targets via RNA-dependent post-transcriptional silencing mechanisms, 
and mRNA transcripts can be regulated by multiple miRNAs
21
. Global reduction of 
mature miRNAs and alterations in miRNA processing were identified in ALS patients 
expressing TDP-43 mutations, specifically deregulated in CSF and serum of SALS 
patients. However, the level between them were altered, suggesting an independent 
regulation of specific miRNAs in the two compartments and a generally low transition 
of miRNA across bloodcerebrospinal fluid barrier
27
 
Epigenetic mechanisms are altered in both explained and unexplained ALS cases; 
however, it remains arguable whether these changes are a cause or consequence of the 
disease.  
2.3.3. Molecular molecular mechanisms 
Also, several molecular mechanisms have been discovered to produce neurodegenration 
in ALS patients. These mechanisms include: excitotoxicity, impaired proteostasis, 
disturbed RNA metabolism, cytoskeleton and axon-transport defects, 
Neuroinflammation, astrogliosis and mitochondrial dysfunction
12
. It is not clear what 
role they play or if they could be a relation between them in ALS pathogenesis. 
However, the same mechanism has been linked to several patients with different 
subjacent cases, even those with genetic and non-genetic primary causes as well as 
different patients with different genetic mutations
12

















C9orf72 x x x    
FUS x x x    
SOD1 x  x x x x 
TARDBP x x   x  







Figure 4. Excitotoxic mechanism developed in ALS neurons
28
. 
Excitotoxicity is the pathological process by which nerve cells are damaged or killed by 
excessive stimulation by neurotransmitters, mostly glutamate. When the glutamate 
concentration around the synaptic cleft cannot be decreased or reaches higher level, the 
neuron kills itself by apoptosis. An increment of the synaptic release of glutamate could 




2.3.3.2. Impaired proteostasis 
 
Figure 5. Miss folding proteins and aberrant protein generation mechanism developed in ALS neurons
28
. 
One of the principal mechanisms of ALS pathogenesis is the excessive formation of 
protein aggregates. These aggregations are formed by misfolded proteins and RNA 
13 
 
components due to problems in the RNA or DNA functioning, or a lack of activity by 
the chaperones. The formation of these aggregates has been linked to patients with 
TARDBP and FUS mutations. These accumulations of misfolded proteins active the 
endoplasmic reticulum (ER) stress response. ER-resident chaperons recognize the 
accumulation of these proteins and activate the Unfolded-Protein Response (UPR) 
which degraded these proteins (see figure 6). Although, prolonged UPR activation can 
trigger apoptotic signaling
30
. Also, the protein aggregates can cross the plasmatic 
membrane, spreading to other motor neurons or non-neural cells. This type of prion-like 
transmission has been postulated as the method of transmission inside the CNS. 
However, has been demonstrated that the neurodegenerative disease cannot infect other 
humans in the same way that other prion diseases do
31
. 
2.3.3.3. Disturbed RNA metabolism and RBP’s 
 
Figure 6. Defective RNA processing mechanism developed in ALS neurons
28
 . 
RNA processing alterations are strongly related to the protein aggregation and other 
pathophysiological mechanisms in ALS. The pathological processing in RNA is due to 
an incorrect functioning of the RNA-binding proteins (RBP). RNA-binding 
proteins are proteins that bind to the double or singlestranded RNA in cells and 
participate in forming ribonucleoprotein complexes. In ALS patients, the RBP control 
the inhibition of the transcription of several genes, like TARDP. Interfere with mRNA 
generation and silencing, produce defective splicing and have a negative effect on RNA 
transport and local translation (see figure 7)
32
. Also, this RNA malfunction could be 
















Figure 7. Axonal defects developed in ALS neurons
28
. 
One of the main findings supporting axonal transport deficits contributing to 
neurodegeneration is the axonal and cell body accumulation of organelles and other 
proteins observed in human neurodegenerative diseases, mainly accumulation of 
neurofilament and impaired proteins. However, axonal transport deficits may evolve 
independently from MN degeneration. It has been demonstrated that axons can survive 
despite long-lasting transport deficits
12
. Another strong hypothesis is the perturbation of 
the Dynein/dynactin complex. This complex is involved in axon maintenance, removal 
of damaged organelles, vesicles, misfolded and aggregated proteins from axons to the 
cell body. Many point mutations in the gene encoding for dynactin were found in 
sporadic and familial cases of ALS. The largest dynactin subunit (DCTN1) which 
mediates dynein–dynactin interaction is a critical component of the whole 
dynein/dynactin complex. The mutations on the genes expressing this subunit show 
accelerated motor neuron degeneration in humans and mice which resembled ALS (see 
figure 8)
33
.   












Mitochondrial dysfunction has been implicated as playing a role in MTNs death in 
ALS. Fragmentation of mitochondria and changes in mitochondrial morphology and 
expression of fusion/fission proteins are well described in ALS and have pronounced 
effects on normal mitochondrial function. In addition, it has been proved that neural 
mitochondria calcium buffering capacity is altered prior to symptoms onset in the brain 
and spinal cord of SOD1 mice
12
. Also, Impairment of calcium buffering in MTNs could 
increase their susceptibility to the altered calcium homeostasis associated with 
glutamate-mediated excitotoxicity. Mitochondria from ALS patients have impaired 
Ca
2+
 homeostasis and an increased production of reactive oxygen species (ROS). 
Besides mitochondrial could have the serious impact, causing apoptosis of the MTNs 
(see figure 9)
28
.  Several small molecules have been developed targeting mitochondrial 
dysfunction such as Cu(II)ATSM and Rasagiline being in phase I/II clinical trials. 
2.3.3.6. Neuroinflamation and astrogliosis 
 
Figure 9. Neuroinflamation processes developed in ALS neurons
28
. 
Neuroinflammation is a common pathological event of neurodegenerative disorders. In 
ALS, MTNs damage leads to the activation of microglia, astrocytes and the complement 
system, further contributing to neurodegeneration
34
. It is accepted that neighboring glial 
cells have a crucial role in the MN degeneration occurring in ALS, modulating ALS 
progression (see figure 10)
28
. Astrocytes also play a key role in secreting inflammatory 
mediators, such as prostaglandin E2, leukotriene B4, and nitric oxide both at basal (non-
activated) and activated conditions. Several small molecules and antibodies are being 
researched in order to improve ALS pathogenesis. The drug NP001 and the antibody 






2.3.4. Rodent models 
For the past twenty years the SOD1 mouse model, mainly the SOD1G93A mouse 
model, has been used to characterize the basic biology of ALS as well as to explore 
specific benefits of potential therapies with questionable success. These mice 
overexpress human SOD1 under control of the human SOD1 promoter and regulatory 
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A major discrepancy between the SOD1 mouse model and patients is that in the 
majority of ALS patients appears to involve aberrant RNA metabolism. Also some 
patients present inclusions ubiquitinated, phosphorylated and comprised cleaved C-
terminal TDP-43 fragments. In order to solve these trammels a TDP-43 mouse model 
was required. Thus, TDP-43 transgenic mice were generated that overexpress either 
mutant or wild type TDP-43 expressed under control of the prion promotor (PrP)
35
.  
Related to other mutation producing ALS, some C9ORF72 knockout or transgenic 
mouse models have been generated. Thus far, they have mainly contributed to 





Due to these difficulties already mentioned, ALS diagnosis remains complex procedure 
and only can be accomplished correctly when the later stages of the disease manifest. It 
also depends on the exclusion of other diseases with similar clinic expression through 
electrophysiological studies, clinical examination and the natural history of the patient. 
It is thought that approximately 22% of ALS deaths happen before a proper diagnosis
37
. 
To improve the diagnosis, the ALS research community proposed the El Escorial ALS 
diagnosis criteria, a group of characters and evidence that establish a guide for 
physicians to diagnose ALS cases correctly
38
. This criterion is under revision 
constantly, the last being the revision of Awaji
39
. Besides, there is an absence of specific 
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2.5. Current treatments  
Currently, there is no cure or drugs available for ALS and only 3 approved drugs to treat 
ALS: Riluzole, Edaravone and Nuedexta
TM
 being Riluzole the only one that increases 
life expectancy between 2 and 3 months
40
. Edevarone and Nuedexta
TM
 only are 
available to treat a specific spectrum of the ALS patients (see figure 12). This lack of 
effective drugs causes the treatment guides to focus only on symptomatic treatment and 
physical therapy, trying to reduce a series of symptoms that difficult the everyday life of 
the patients.  
Nowadays, and due to the lack of biomarkers, the rate of ALS progression can be 
measured using an outcome measure called the "ALS Functional Rating Scale Revised 
(ALSFRS-R)", a 12-item instrument administered as a clinical interview or self-reported 
questionnaire
41 
it is the most commonly used outcome measure in clinical trials and is 
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Sigma-1 receptor (S1R) 















Edaravone has been a recent success in the ALS new drug approval history. It was 





antioxidant mechanism of Edaravone seems to increase prostacyclin production, 
decrease lipoxygenase metabolism of arachidonic acid by trapping hydroxyl radicals, 
and inhibit alloxan-induced lipid peroxidation and quench active oxygen
54
. Edaravone 
show difficulties during its trials, because a first phase III clinical trial was performed 
didn’t show a significant variance between the placebo and Edaravone treatment 
group
44
. It was not until a post-hoc clinical trial based on the first one but with more 
restrictive patient condition (patients with a shorter disease duration and a larger vital 





Riluzole is the oldest drug approved for the ALS treatment. Its use has now been well-
established as consistently extending lifespan. At low concentrations (<1-10μM), 
riluzole suppress the persistent Na
+
 current and enhance the calcium-dependent K
+ 
canals. In higher concentration (20–100 μM), the inhibition affects the voltage-
dependent A-type or delayed rectifier K
+
 currents, which can modulate neural 






Pseudobulbar affect (PBA), or emotional incontinence, is a type of emotional 
disturbance characterized by uncontrollable episodes of crying and/or laughing, or 
other emotional displays, produced most of the time in inappropriate contexts. PBA 
affects 25% of ALS patients, mostly when the upper MTNs are affected
46
. In 2013, the 
European Medical Agency approved Nuedexta
TM
. This drug contains two active 
compounds, the Dextromethorphan and Quinidine sulfate. Even though, the exact way 
dextromethorphan works in PBA is unclear, it is thought that it may bind to NMDA 
receptors (impairing the glutamate action) as well as on 5-HT1A receptors. The role of 
the quinidine is to prevent Dextromethorphan from being broken down early in the 
body.  
2.6. Objectives  
This report attempts to explain the ALS disease from its hypothetical causes to the 
actual treatments and new therapeutic strategies in current clinical trials. Thus, the main 
scope of the report is Pharmacology, because the research about the current, future and 
possible future treatment of ALS and the explanation of why there is no treatment to 
cure or chronify the disease past two centuries since its discovery, are the main 
objectives to treat in this report. However, due to the overview nature of the report, 
other scopes appear in it, being Physiopathology and Biochemistry the more prominent 
ones. They are going to be discussed further when talking about the disease 
mechanisms. Besides, other scopes are treated in the report, but with less depth such as: 
toxicology or public health. 
This principal objective could be extended in 4 concrete objectives:  
1. Understand the pathophysiology of the disease. 
 
2. Discuss the efficacy and safety of the current treatments. 
 
3. Expose the trends in ALS drug discovery. 
 
4. Display current drugs under clinical trials.  
19 
 
3. Methodology and methods 
This report is a continuation of investigation realized in the Neurodialitics research unit, 
belonging to the University of Lyon, in 2016. At that time, first started by proposing a 
scheme in which the report is going to be based, clarifying the process and madding 
clear every step. Then, the research information began with the ALS patient foundations 
principally the American, Spanish and Catalan. These pages have easy information 
mostly directed to patients and familiars that do not have biology and pharmacological 
knowledge. Therefore, provide an excellent first source of information going through 
the basics of the disease, natural history, and actual treatments. 
At that point, realizing the insufficient actual ALS treatment, and the poor prognosis 
and natural history of this disease, decided to research more indepth information 
regarding pathophysiological mechanism, drug discovery linked to these mechanisms 
and the actual clinical trials taken place. Mainly reviews, articles and some books 
provided that information. Most of them being free–access found in the main databases 
(Pubmed, Scopus, Researchgate and Medline). Besides, this information was 
complemented by the University of Barcelona and Lyon databases. The articles were 
written mostly in English, but some were found written in Spanish and French, and with 
that form a first raw database. Regarding the pathophysiological mechanism, the review 
of Xavier Navarro and Renzo Mancuso
12
 two researchers from the Universitat 
Autònoma de Barcelona (UAB) is one of the most complete and actual reviews of this 
topic. This review constituted a first start and background for the report. Similarly, on 
drug discovery information, the review by the Deloanch et al.
48
 conducted by the group 
of Mahmoud Kiaei was also considered a primary stand point. This group of researchers 
from the University of Arkansas for Medical Science specialized in neurodegenerative 
disease and focused in ALS with several previous works on the topic. Then, realizing 
that these two reviews were written in 2015, the research was focused on finding new 
information from 2016 and forward. Also, for the last part of the report, regarding 
current ALS clinical trials, the webpage clinical.gov was proven a useful resource. This 
webpage is provided by the U.S. National Library of Medicine and publicly funded. 
Collecting all the information regarding all the clinical trials from phase I to phase III 
that are currently running or have been finished. 
Developing this report, new information comes out almost every day. Thanks to my 
tutor, once the research was based on Barcelona, could reorientate the report and stay on 
track while all these information was coming. This continuous flow of new information 
made the realization of this report exciting and interesting. Also, it made sure that a 




4. Results  
4.1. Drugs in Phase I/II 
Nearly 50 clinical trials for disease-modifying treatments have been undertaken in the 
past half-century. The FDA approval rate of investigational compounds from the time 
they first entered clinical trials is about 16% for trials initiated by pharmaceutical 
companies.23 RCTs (of 18 different drugs) completed in the past decade 22–47 were 
progressively better organized than previous trials, but had recurrent and similar issues. 
Six different hypothetical, pathogenic targets underlie the rationale for these RCTs, 
which were undertaken on the basis of the hypothetical therapeutic targets and evidence 
derived from superoxide dismutase (SOD1) transgenic mouse models, previous studies 
in human beings, or both
64
. Since then, a smaller number of pathogenic targets have 
been tried. Taking as a representation the drugs that nowadays are in phase I and II (see 
figure 13), we observe that they have been reduced to the protection of the 
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4.1.1.Cu(II)ATSM and Rasagiline 
As mitochondrial protector we can found Cu(II) ATSM and Rasagiline. Cu(II)ATSM is 
a bisthiosemicarbazone which selectively delivers copper to cells with impaired 
mitochondrial electron transport chains, a characteristic of ALS and many other 
neurodegenerative diseases. In both SOD1 mouse models of ALS and in ALS patients, 
scientists have found alterations in copper homeostasis, providing a rationale for testing 
this candidate in ALS. In a series of publications in mouse models of ALS, 
Cu(II)ATSM improved motor function and prolonged survival
7
. Rasagiline is an 
inhibitor of type B monoamine oxidase (MAO-B). It is thought to help protect neurons 
by bolstering mitochondria by suppressing Ca(2+) efflux through the mitochondrial 
permeability transition pore (Wu et al., 2015). A phase II clinical trial is ongoing. 
4.1.2.Mexiletine and Retigabine 
As neural excitability protectors we can found Mexiletine and Ratigabine. Mexiletine is 
a sodium channel blocker that may reduce neuronal hyperexcitability by reducing 
sodium ion influx (the persistent sodium current). A phase II study is currently 
recruiting. The study aims to determine whether mexiletine may slow progression of 
ALS, and/or reduce muscle cramps and twitching in the disease
7
. Retigabine is a Kv7 
potassium channel activator that may reduce neuronal hyperexcitability by helping 
neurons return to the resting state upon firing. The phase 2 clinical trial of retigabine in 
ALS is ongoing.  
4.1.3.Immunomodulators 
As said before, neuroinflammation is a common pathological event of 
neurodegenerative disorders.  It is accepted the activation of microglia, astrocytes and 
the complement system, play a key role contributing to neurodegeneration
34
. 
Immunomodulators are one of the principal focus on ALS research and we can found 
several drug in clinical trials.  
Ibudilast is an orally bioavailable, centrally acting phosphodiesterase inhibitor that 
attenuates glial cell activation, at least in part, by reducing the effect of proinflammatory 
factors. MN-166 may minimize the production of pro-inflammatory cytokines
7
. 
AMX0035 a proprietary combination of two drugs, TUDCA and sodium 
phenylbutyrate, that acts by reducing cell death and neuronal inflammation in response 
to oxidative insult. The phase II clinical trial launched in June 2017
7
. 
NP001 is a small molecule regulator of macrophage activation. It is thought to restore 
macrophages to their neuroprotective state and reduce inflammation seen in ALS. 
Treatment of ALS mouse models with NP001 extended survival. In the Phase IIa safety 
study, administration of a high dose of NP001 (2mg/kg) over a 6 month period was 
associated with a slowing of disease progression in 27% of patients, approximately 2.5 
22 
 
times greater than the percentage in patients on placebo (10%). A Phase II study was 
completed in 2012. A confirmatory Phase II study is ongoing. Neuraltus is establishing 
a managed access program for ALS patients in Europe
7
. 
 Tocilizumab may reduce neuroinflammation by lowering levels of the pro-
inflammatory cytokine IL-6. The drug, which is a monoclonal antibody, competitively 




4.2. Current drugs in Phase III clinical trials. 
The lack of new drugs approved during the past 2 decades has not intimidates researcher 
that keep trying to find a new drug that could improve ALS actual pathogenesis. Even 
though, only few drugs from the preclinical trials arrive at a phase III, in this report is 
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Arimoclomol acts stimulating the cells’ heat shock response, the protective system 
involved in maintaining proper protein folder. However, it acts as a “smart drug” to co-
induce the heat shock response only in cells already under stress
49
. This ability to focus 
the damaged cells, suggest that this approach may have therapeutic value in 
neurodegenerative disorders, in which neurons are under prolonged stress. Arimoclomol 
have been tried in a phase II randomized, double-blind, placebo-controlled trial that 
included 36 patients with rapidly progressive ALS due to mutations in the SOD1 gene. 
This clinical trial has been the first one including only certain types of ALS patients
50
. 
In previous trials, Arimoclomol has proved to be beneficial in the SOD1 ALS patients, 
even when administered after symptom onset. In all phase I and phase II clinical trials to 







Masitinib is a tyrosine kinase (TK) enzyme inhibitor developed by the French company 
AB Science
52
. The activation of TK is central to the ability of immunoglobulin E to 
transmit downstream signaling events required for the regulation of mast cell 
activation
53
. An inhibition of TK could inactive the mast cells and macrophages in the 
nervous system and be able of controlling microgliosis, neuroinflamation, and the 
emergence/expansion of aberrant glia cells. In preclinical studies, Masitinib 
significantly prolonged survival when delivered after paralysis onset in SOD1 rats
54
.  
These facts encouraged the Masitinib clinical trials, starting a phase III clinical trial in 
December 2015. The study was a blinded, placebo-controlled, 3-treatment arms 
(randomization 1:1:1), testing Masitinib 4.5mg/kg/day + Riluzole, Masitinib 
3mg/kg/day + Riluzole and Placebo + Riluzole. The treatment duration was 48 weeks, 
and a total of 392 patients were enrolled in the study, a 2/3 in Europe and 1/3 outside 
Europe (Argentina and Canada)
55
.  
Masitinib orally administered at 4.5 mg/kg/day as an add-on to Riluzole demonstrated a 
significant therapeutic benefit with acceptable safety in ALS patients with a baseline 
ALSFRS-R progression rate of <1.1 points / month (see figure 16). Also, Significant 
benefit on key secondary endpoint the PFS, which is defined as the earliest event 




Figure 10. Graphic showing the PFS comparison between Masitinib and Placebo patient group
 56
. 
However, these results were insufficient to The Committee for Medicinal Products for 
Human Use (CHMP) of the European Medicine Agency (EMA), adopting a negative 
opinion for the marketing authorization of Masitinib in the treatment of adult patients 
with Amyotrophic Lateral Sclerosis. In the near future, AB Science will provide 









MSC-NTF cells are Mesenchymal Stromal Cells (MSC) induced to express high levels 
of neurotrophic factors (NTFs) using a culture-medium based approach. These MSC-
NTF cells were found to alter the miRNA proportions in the human DOD1 transgenic 
mouse model of ALS. To elucidate the potential of MSC-NTF in ALS treatment a 
preclinical study was made to determine whether the miRNA profile could provide a 
tool for MSC-NTF cell characterization and to distinguish them from the matched MSC 
from which they are derived. Principal component analysis revealed two distinct 
clusters based on cell type (MSC and MSC-NTFs). Nineteen miRNAs were found to be 
upregulated and 22 miRNAs were downregulated in MSC-NTF cells relative to the 
MSC cells of origin. In an analysis of the mRNA targets, three mRNA targets of hsa-




After this success, a phase II clinical trial has been finished recently with success
59
. The 
study evaluate the safety, tolerability and therapeutic effects of transplantation of 
escalating doses of autologous cultured mesenchymal bone marrow stoma cells 
secreting neurotrophic factors (MSC-NTF), in patients with amyotrophic lateral 
sclerosis (ALS). The study was conducted in Israel at Hadassah Medical Center and 
three medical centers in the United States at Mayo clinic, MGH (Massachusetts General 
Hospital) and UMass (University of Massachusetts). The trial was 48 patient 
randomized, double-blind with placebo-controlled groups. The trial revealed a 
statistically significant improvement in the rate of ALSFRS-R progression (see figure 
17) for those with complete follow-up. The results suggest that IT and IM 
administration of MSC-NTF cells in patients with ALS is safe and provide indications 
of possible clinical benefits, to be confirmed in upcoming clinical trials
60
. 











ALSFRS-R       
Phase 1 / 2 (n=6) 24.8 -1,56 -0,98 -0.28 37% 82% 
Phase 2a (n=14) 39,9 -1,41 -0,78 -0,60 45% 57% 
Pooled per protocol 
(n=15) 
 -1,2 -0,6  50% 
 








5 . Discussion 
Amyotrophic lateral sclerosis is a dreadful neurodegenerative disease affecting the life 
of the patients and their families even previous the diagnosis. The loss of lower MTNs 
affecting limbs and upper MTNs producing PBA, produce a disabling disease that 
difficult the everyday life to patients and caregivers. ALS progress tireless since its 
onset, auguring a fatal final for which still no cure yet.  
ALS is spread all across the globe without difference of location, gender and 
socioeconomic status. Except for particular cases in history such as the indigenous 
tribes of Guam Island and the Gulf War US veterans (which are being studied 
carefully). 
The linkage of some ALS cases to genetic mutations
13 
supposes a great improvement in 
ALS research, especially the C9orf72 intron hexanucleotide repetition discovering that 
allowed to explain almost 70% of fALS cases and 10% of sALS cases
16
.Even though, 
the most predominant genes (which have been explained in this report) have a clear 
relation with ALS, their mechanism still not fully understood. For example, the fact that 
a loss function mechanism could not be involved in SOD1 mutation is not clear. In 
addition, more data is needed to elucidate if C9orf72 mutations affect RNA processes as 
well as creates RNA misfolded aggregation, and to fully understand the prion-like 
mechanism of transmission in patients with TDP-43 and FUS mutations
12
. Besides, 
improvements in nucleotide sequencing and drop in sequencing cost will permit large-
scale exome/genome sequencing, helping to generate new candidates that could 
improve the ALS genetic understanding
61
. 
An epigenetic subjacent cause has been proposed to explain these genetic discrepancies 
and involvements in ALS onset.  Epigenetic mechanisms are altered in both explained 
and unexplained cases; however, it remains arguable whether these changes are a cause 
or consequence of the disease. For example, DNA methylation and altered histone 
modifications around expanded hexanucleotide repeats in C9orf72 are most likely a 
consequence, as the expansion itself is a cause of the disease. On the other hand, the 
role of altered miRNA expression is less apparent; it may be a cause of the disease, 




Several pathophysiological mechanisms still not fully understood. Perturbation of 
axonal transport, especially in SOD1, may increase inflammatory and excitotoxic 
mediators, altering mitochondria or damaging transport cargos, despite the misfolded 
tubulin and protein accumulation. Showing that it is not clear if one mechanism triggers 
the others or a subjacent unknown cause triggers one or several of these mechanisms. 
Also, with the same mechanism linked to several patients with different subjacent cases 
difficult to establish a coherent linear mechanism. However, Mitochondria dysfunction, 
the accumulation of oxidative species and involvement of glial cells and other immune 
cells seems to play a principal role in ALS together with excitatory mechanism. So far, 
26 
 
thus are the mechanisms that have responded to treatment targeting them, despite the 
lack of clear data
12
.  
One of the major problems associated with the development of effective ALS treatments 
is the inadequacy of the animal models. Indeed, despite the wide use of mouse models 
for ALS in biomedical research, they would mimic only partial aspects of human 
pathology, often leading to a consistent lack of concordance between the preclinical and 
clinical studies. Therefore, a better understanding of the similarities and differences 
between the animal and human ALS pathophysiology is of fundamental importance to 
the rational identification of therapeutic interventions capable of stopping or at least 
effectively modifying the course of ALS
62
. Besides, the utilization of just a single-
disease model for research is not without risks by combining the use of several model 
systems and capitalized on the strength of each organism to screen large chemical 
libraries in the search for potential therapeutic drugs for ALS
63
. More epigenetic 
understanding also could bring the possibility of the epigenetic mouse model that could 
bring a new scope on the limited library of models that researcher dispose of in the 
actuality. In addition, a research program with the objective of reprogramming ALS 
patients’ fibroblasts into induced pluripotent stem cells (iPSC) appears as a promising 
opportunity to develop sALS models. These cells have been differentiated into ALS-
relevant cell subtypes including MN and atrocities, among others
12
.This type of cells are 
being also tested as a possible treatment without reprogramming them (see part 4.2.3. 
Nurown). 
Possibly the main difficult in the advance of finding a cure for ALS it is behind the 
clinical trials. Even though, the latest success of Edaravone, approved last year to treat a 
specific type of ALS patients (see part 4.2.1), more than 50 randomized controlled trials 
(RTC) had been performed in the past half-century with negative results
64
. The research 
community has proposed several answers trying to explain these negatives results. First 
of all, the heterogeneous, pathogenesis of ALS remains mostly unknown. This fact 
merged with the rapidly fatal and so far intractable nature of the disease, produces the 
research community tends to welcome new ideas or hypotheses
64
. Secondly, therapeutic 
approaches in animal models are usually applied prior to clinical onset of the disease. 
Despite this strategy might offer better results in preclinical studies and could be 
relevant for fALS cases, it cannot be replicated in human sALS
12
. Also there is the 
possibility that the data obtained from the Phase II RTC is being potentially misleading 
since a lot of these compounds accomplish to succeed in this RTC after failing in phase 
III RTC.  
These enrolment problems could be solved by restricting the conditions for the patients. 
The Edaravone clinical trial reflects a growing trend in ALS studies to try to divide 
study populations into subgroups that might be more likely to benefit from compounds 
clinical sub grouping. Different therapeutic compounds may have efficacy in other ALS 
subgroups besides those chosen in this development programmed. However, identifying 
those specific subgroups remains a challenge which will perhaps be addressed through 





Regarding new developments, the recent focus on mitochondrial dysfunction, neural 
excitatory and immunomodulation could be a temporary trend because no recent key 
development in ALS has been reached lately. Obviously, these clinical trials are started 
based on new pathophysiological information, but that do not mean a possible success 
could be expected, if we take the past 50 years of research into consideration.  However 
new approaches to clinical trials, as said earlier, and drug development could lead to 
new approved drugs. Examples of that are Ariclomol with its “smart drug” approach or 
NurOwn starting a steam cells treatment. These new approaches could signify new 
hopes for ALS development, still to be confirmed in their respective phase III clinical 
trials. 
Lastly, the most pressing need in the field is for biomarkers that will be most relevant to 
therapy development. Discovery and early development of such biomarkers will 
appropriately utilize samples housed within established repositories. However, the 
development and clinical validation of biological fluid-based pharmacodynamic and 
disease progression biomarkers will require prospective as well as standardized 




1.ALS is a complex disease with the genetic, epigenetic and several pathophysiological 
mechanism involvements that difficult a complete understanding about it. 
2.The only treatment available that improves the survival expentacy is Riluzole. 
Neudexta and Edaravone only act in a small range of ALS patients, they lack an 
effective treatment at the moment. 
3.Mitochondrial dysfunction, Neural excitatory and immunomodulation are the 
predominant therapies under investigation right now. However, further development 
could be needed to bring those hypotheses into actual treatments. 
4.New drugs with new innovative approaches, far from current mechanism focus, could 
be success in the next years, establishing the actual trend of more biological treatments 
in front of more chemical ones. 
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